Stocks in the News: Celgene Breaks Out

Posted: Jul 11, 2013 12:01 AM

Stocks in the News is produced by Ransom Notes Radio and Goodfellow, LLC. Crista Huff manages Goodfellow LLC, a website that recommends outperforming stocks using fundamental and technical analysis. 

Stock number one is: 

Ford Motor Co., (SYMBOL: F) and the headline says:

Tesla to Ford Top 100-Week Highs as U.S. Automakers Surge

Auto stock prices are surging to recent highs along with strong demand for U.S. cars and trucks.  “Demand is being fueled by pent-up need, historically low interest rates, and newly competitive compacts and family cars that are winning converts to U.S. automakers,” reports Bloomberg.

We recommended shares in Ford Motor Company in May and June.  Shares are up 26% since then, and still climbing, on expectations of strong future earnings growth.  The dividend yield is 2.4%.

Ford shares are approaching medium-term resistance at $19.  Investors should expect a pullback at that point.

Our Ransom Note trendline says:  HOLD FORD MOTOR COMPANY.

Stock number two is: 

Barnes & Noble, Inc., (SYMBOL: BKS) and the headline says:

First quarter loss of $0.78 per share anticipated for Barnes & Noble  -- Reuters

Nationwide book retailer Barnes & Noble continues to lose money as it works through management and cash flow difficulties.  CEO William Lynch recently resigned, which could signal an upcoming sale of the problematic Nook division, and a renewed focus on retail business.

Annual net losses are projected to reach from 2011 through 2016 and possibly farther out.

There’s no logical reason for anybody to own the stock, yet it’s trading between $15 and $24.  We would sell in the low $20’s and invest in a profitable company.

Our Ransom Note trendline says: SELL BARNES & NOBLE.

Stock number three is:

Celgene Corp., (SYMBOL:  CELG) and the headline says:

S&P Reiterates Strong Buy Opinion on Celgene – Standard & Poor’s Research

Shares of biopharmaceutical company Celgene Corp. are breaking through upside resistance today on positive Phase III data on its myeloma cancer drug, REVLIMID.  The company will likely file for global regulatory approval this year.  S&P raised its target price  today to $157.

Celgene’s earnings are projected to grow 17%, 21% and 28% over the next three years.  The PE is 23.

The share price is up 25% since we began recommending Celgene on March 5.  New investors are encouraged to jump in on today’s breakout.

Our Ransom Note trendline says: BUY CELGENE.